Mink Therapeutics, Inc. Stock Price, News & Analysis

MiNK Therapeutics (NASDAQ: INKT) has announced an upcoming presentation at the ASCO GI Symposium in San Francisco from January 23-25, 2025. The presentation will focus on their ongoing Phase 2 study of agenT-797, an invariant natural killer T (iNKT) cell therapy, combined with Agenus' botensilimab/balstilimab for treating refractory gastric cancer.

The abstract (TPS515), titled 'A phase II study of agenT-797, botensilimab, and balstilimab in patients with advanced, refractory gastroesophageal adenocarcinoma,' will be presented by Dr. Samuel Cytryn during the Trials in Progress Poster Session on January 23, 2025. Complete abstracts will be released on January 21st, 2025, at 5:00 PM ET, with presentation materials later available on MiNK's website.

MiNK Therapeutics reported Q3 2024 financial results and business updates. The company ended Q3 with $6.3 million cash balance, with reduced cash burn of $3 million for Q3 and $7.8 million for nine months of 2024. Net loss was $1.8 million ($0.05 per share) for Q3 and $8.3 million ($0.22 per share) for nine months.

Key developments include Dr. Robert Kadlec joining the Board, a research collaboration with Autonomous Therapeutics for metastatic tumors, and two presentations at SITC 2024. The company's Phase 2 trial for gastric cancer is ongoing with data expected in early 2025, and a Phase 1 GvHD trial is planned for 2025.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on invariant natural killer T (iNKT) cell therapies, announced it will release its third quarter 2024 financial results before market opens on November 14, 2024. The company will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update. The event will be accessible via phone and webcast through the company's investor relations website.

MiNK Therapeutics presented new data at SITC 2024 showcasing their iNKT cell therapy programs. Their lead therapy agenT-797, alone or combined with anti-PD-1, demonstrated durable disease control in heavily pretreated patients. When combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, and DLL3, it showed enhanced T-cell activation and tumor cell killing.

The company also presented data on their PRAME-TCR iNKT therapy, designed to treat PRAME-positive solid tumors without requiring lymphodepletion or HLA-matching. A Phase 2 trial of agenT-797 is currently enrolling patients with advanced gastroesophageal cancer, with results expected in 2025.

MiNK Therapeutics (NASDAQ: INKT) has appointed Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec, former U.S. Assistant Secretary for Preparedness and Response at HHS, brings extensive expertise in biodefense and pandemic preparedness. He previously co-conceived Operation Warp Speed and directed pandemic response for HHS during COVID-19. His appointment aims to accelerate MiNK's development of allogeneic off-the-shelf invariant natural killer T (iNKT) cell therapies for infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS) and emerging threats.

MiNK Therapeutics (NASDAQ: INKT) announced two poster presentations at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston, Texas, from November 6-10, 2024. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.

The first presentation, titled 'AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response,' is scheduled for Friday, November 8th (Abstract Number: 753).

The second presentation, 'PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME,' will take place on Saturday, November 9th (Abstract Number: 374).

MiNK Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focusing on allogeneic iNKT cell therapies, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024. Dr. Jennifer Buell, CEO of MiNK, will engage in a fireside chat on Monday, September 9th at 7:00 a.m. ET.

Investors can register for the event online, and a replay will be available on MiNK's website afterward. This conference provides an opportunity for MiNK to showcase its progress in developing innovative therapies for cancer and other immune-mediated diseases to a global investment audience.

MiNK Therapeutics (NASDAQ: INKT) reported Q2 2024 results and provided a business update. Key highlights include:

• Expanded access to AgenT-797 in severe ARDS shows clinical efficacy
• Phase 2 study in 2L gastric cancer advancing with early data expected soon
• Phase 1 study in GvHD on track for activation in Q2 2024
• Successful PIPE financing raised $5.8 million at 25% premium
• Cash runway extended into 2025
• Q2 net loss of $2.7 million ($0.07 per share), down from $6.2 million ($0.18 per share) in Q2 2023
• Cash balance of $9.3 million as of June 30, 2024

MiNK is advancing its iNKT cell therapy programs, with promising results in ARDS and plans to fast-track IND filing for MiNK-215 CAR-iNKT therapy to early 2025.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has announced its plans to release second quarter 2024 financial results on August 13, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update. Interested parties can access the call via provided dial-in numbers or join the live webcast through the company's investor relations website.